...
首页> 外文期刊>Oncology reports >Improved xenograft efficiency of esophageal adenocarcinoma cell lines through in vivo selection
【24h】

Improved xenograft efficiency of esophageal adenocarcinoma cell lines through in vivo selection

机译:通过体内选择改善食管腺癌细胞系的异种血症效率

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The present study aimed to investigate the orthotopic growth potential of two generally available esophageal adenocarcinoma cell lines, OE33 and OACM5 1.C, and a third in vivo selected subpopulation, OACM5 1.C SC1. One group of mice was subcutaneously injected in the hind legs. Tumor growth was measured with calipers. Another group was injected orthotopically in the distal esophageal wall through median laparotomy. Tumor development was evaluated macroscopically and confirmed microscopically. A subset of mice was evaluated with magnetic resonance imaging (MRI) to follow tumor progression. Additionally, functional cell line characteristics were evaluated in vitro (clonogenic, collagen invasion and sphere formation assays, and protein analysis of cell-cell adhesion and cytoskeletal proteins) to better understand xenograft behavior. OE33 cells were shown to be epithelial-like, whereas OACM5 1.0 and OACM5 1.0 SC1 were more mesenchymal-like. The three cell lines were non-invasive into native type I collagen gels. In vivo, OE33 cells led to 63.6 and 100% tumor nodules after orthotopic (n=12) and subcutaneous (n=8) injection, respectively. Adversely, OACM5 1.0 cells did not lead to tumor formation after orthotopic injection (n=6) and only 50% of subcutaneous injections led to tumor nodules (n=8). However, the newly established cell line OACM5 1.0 SC1 resulted in 33% tumor formation when orthotopically injected (n=6) and in 100% tumors when injected subcutaneously (n=8). The higher xenograft rate of OACM5 1.0 SC1 (P<0.05) corresponded with a higher clonogenic potential compared to its parental cell line (P<0.0001). All models showed local tumor growth without metastasis formation. In conclusion, OACM5 1.0 has a poor tumor take rate at an orthotopic and ectopic site. A subpopulation obtained through in vivo selection, OACM5 1.0 SC1, gives a significant higher take rate, ectopically. Furthermore, OE33 establishes orthotopic (and subcutaneous) xenografts in mice. These models can be of interest for future studies, and their slow growth rates are a challenge for therapeutic intervention.
机译:本研究旨在探讨两种通常可用食管腺癌细胞系,OE33和OACM5 1.C的原位生长潜力,以及第三个在体内选择的亚泊素,OACM5 1.C SC1。在后腿中皮下注射一组小鼠。用卡钳测量肿瘤生长。通过中位曲面术,在远端食道壁上注射另一组。肿瘤发育在宏观上进行评估并进行显微镜。用磁共振成像(MRI)评估小鼠的一组,以遵循肿瘤进展。另外,在体外评估功能性细胞系特性(克隆,胶原蛋白侵袭和球形形成测定和细胞 - 细胞粘附和细胞骨骼蛋白的蛋白质分析)以更好地理解异种移植行为。显示oe33细胞是上皮样的,而OACM5 1.0和OACM5 1.0 SC1更为密闭的样。三种细胞系是非侵入性的I型胶原凝胶。在体内,OE33细胞分别在原位(n = 12)和皮下(n = 8)注射后63.6和100%肿瘤结节。不利地,OACM5 1.0细胞在原位注射后(n = 6)后没有导致肿瘤形成,并且只有50%的皮下注射导致肿瘤结节(n = 8)。然而,当皮下注射时(n = 8)时,新建立的细胞系OACM5 1.0 SC1导致肿瘤形成33%的肿瘤形成。与其亲本细胞系相比所有模型均显示出局部肿瘤生长而不形成转移形成。总之,OACM5 1.0具有较差的肿瘤,在原位和异位位点均采取率。通过体内选择,OACM5 1.0 SC1获得的亚群,斑块均匀占用速率显着较高。此外,OE33在小鼠中建立原位(和皮下)异种移植物。这些模型对于未来的研究可能感兴趣,并且他们的缓慢增长率是治疗干预的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号